Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHTCF.L Regulatory News (HTCF)

  • There is currently no data for HTCF

Statement re September Factsheet

20 Oct 2015 07:00

RNS Number : 7360C
BlueCrest AllBlue Fund Ltd
20 October 2015
 



FOR IMMEDIATE RELEASE

 

20 October 2015

 

BLUECREST ALLBLUE FUND LIMITED

FACTSHEET - SEPTEMBER 2015

"A solid performance against difficult markets"

 

BlueCrest AllBlue Fund Limited (BCAB) rose by 0.3% in September, a solid performance against a backdrop of difficult markets, bringing the gain for the year to date to 2.9% (Sterling Class NAV). The rolling 12 month return remained level at 3.8% and volatility was stable, at 3.2%.

 

Markets were nervous and choppy as economic data remained generally disappointing, particularly from China. Emerging markets continued to feel the strain and the MSCI Emerging Markets index finished September down 17% on a year to date basis. Credit markets also suffered and exhibited some illiquidity, particularly in high yield. The US Federal Reserve keeping rates unchanged did nothing to settle investors' stomachs.

 

"Strongest performance came from BlueTrend 2x"

 

As in August, five of the seven underlying strategies generated positive performance. BlueCrest Multi Strategy Credit and BlueCrest Quantitative Equity detracted once again, albeit only modestly.

 

The strongest performance came from BlueTrend 2x, which rose by over 4.5% on the month. Although only three of BlueTrend's seven strategies produced positive performance, the four detracting strategies did little to dent to strong gains coming from long positioning in bonds, an orientation which was maintained by the model for the entire month. Strong performance was also seen from the short term interest rates sector. Positioning in equities and commodities was maintained net short. Overall risk levels increased slightly during the month.

 

Despite the turmoil in emerging markets, BlueCrest Emerging Markets Fund eked out a small gain. BlueCrest Multi Strategy Credit was the worst performing fund in September at -0.6% on the month. Gains were seen in volatility trading and convertible bond arbitrage with losses in long/short strategies. High yield positioning was largely flat despite illiquidity in the cash bond market seeing some sharp price falls. The risk exposure in the fund was already defensive entering September and there were further modest tactical risk reductions during the month.

 

BlueCrest Mercantile produced a small positive return as both the Trade Credit Opportunities and Bank Basel III strategies were positive. The former saw the Ukrainian sovereign CDS hedges triggered by default but the underlying trade finance positions pay out in full. The Bank Basel III strategy produced the majority of returns as emerging market mark-downs were offset by CDS hedge protection. Small losses were seen from some mining positions. A good pipeline of securitisations is being seen which are expected to become available by year end.

 

A small increase of 1.5% was made to the allocation to BlueCrest Equity Strategies for October at the expense of BlueTrend 2x and BlueCrest Capital International.

 

"The Company continued its buyback"

 

The Company continued its buyback activity during September, although selling pressure has subsequently abated. The discount remains reasonably stable, either side of 5%.

Disclaimer:

This document is directed only at: (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005; or (ii) high net worth bodies corporate, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and persons who receive this document who do not fall within (i) or (ii) above should not rely on or act upon this document.

 

This document is issued by BlueCrest AllBlue Fund Limited (the "Company") to and for the information of its existing shareholders and does not in any jurisdiction constitute investment advice or an invitation to invest in the shares or any other securities of the Company or any other entity (body corporate or otherwise).

 

The Company has used reasonable care to ensure that the information included in this document is accurate at the date of its issue, but does not undertake to update or revise the information, including any information relating to AllBlue Limited and its underlying funds (the "Funds") provided by BlueCrest Capital Management (UK) LLP or any member of the BlueCrest group of companies (as applicable) ("BlueCrest"), or guarantee the accuracy of such information. To the extent permitted by law neither the Company, the Funds, BlueCrest nor their directors or officers shall be liable for any loss or damage that anyone may suffer in reliance on such information.

 

The information in this document may be changed by the Company at any time. Past performance cannot be relied on as a guide to future performance. The Company's investment strategy is speculative and entails substantial risks. The value of an investment may go down as well as up and some or all of the total amount invested may be lost. This document may not, in whole or in part, directly or indirectly, be taken, transmitted or distributed into the United States of America, its territories or possessions or made available to any national, resident or citizen of the United States of America or any other jurisdiction where applicable laws prohibit its release, distribution or publication. Any failure to comply with these restrictions may be a violation of the law in relevant jurisdictions.

 

JTC (Guernsey) Limited

Secretary

 

Tel: Guernsey 01481 702400

 

END OF ANNOUNCEMENT

E&OE - in transmission

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRUKAVRVAARAAA
Date   Source Headline
8th Dec 20219:50 amRNSAquisition of Praxis Fund Services by Sanne Group
3rd Dec 20217:00 amRNSCompany Update
2nd Dec 20213:12 pmRNSNet Asset Value(s)
2nd Dec 20213:12 pmRNS2019 Redemption Portfolio
30th Nov 20214:00 pmRNSTotal Voting Rights
24th Nov 20211:04 pmRNSDirector/PDMR Shareholding
5th Nov 20215:06 pmRNSReturn of Capital to Shareholders
2nd Nov 20214:18 pmRNS2019 Redemption Portfolio
2nd Nov 20214:17 pmRNSNet Asset Value(s)
28th Oct 202112:31 pmRNSResult of AGM
7th Oct 202111:51 amRNSHolding(s) in Company
7th Oct 20217:00 amRNSNotice of AGM
6th Oct 202111:50 amRNSHolding(s) in Company
1st Oct 20211:11 pmRNSNet Asset Value(s)
1st Oct 202112:55 pmRNS2019 Redemption Portfolio
20th Sep 20213:48 pmRNSHalf-year Report
14th Sep 20212:21 pmRNSDirector/PDMR Shareholding
1st Sep 20212:58 pmRNS2019 Redemption Portfolio
1st Sep 20212:55 pmRNSNet Asset Value(s)
31st Aug 20214:40 pmRNSHolding(s) in Company
27th Aug 20217:00 amRNSHolding(s) in Company
19th Aug 20214:00 pmRNSTotal Voting Rights
12th Aug 20214:00 pmRNSReturn of Capital to Shareholders
4th Aug 20215:07 pmRNS2019 Redemption Portfolio
4th Aug 202110:23 amRNSNet Asset Value(s)
27th Jul 20219:15 amRNSDirector Declaration
5th Jul 202112:15 pmRNSApproximate Asset Exposure of the Company
29th Jun 20214:44 pmRNS2019 Redemption Portfolio
29th Jun 20214:38 pmRNSNet Asset Value - Month End Final
21st Jun 20218:31 amRNSDirector/PDMR Shareholding
28th May 20214:30 pmRNSTotal Voting Rights
27th May 20217:00 amRNSHolding(s) in Company
25th May 20214:57 pmRNS2019 Redemption Portfolio
25th May 20214:54 pmRNSNet Asset Value - Month End Final
25th May 20217:00 amRNSDirector/PDMR Shareholding
17th May 202112:54 pmRNSReturn of Capital to shareholders
6th May 20214:48 pmRNSNet Asset Value - Month End Final
6th May 20214:48 pmRNS2019 Redemption Portfolio
22nd Apr 20213:24 pmRNSReturn of Capital to Shareholders
22nd Apr 20217:00 amRNSAnnual Report and Financial Statements
25th Mar 20215:15 pmRNS2019 Redemption Portfolio
25th Mar 20215:14 pmRNSNet Asset Value - Month End Final
5th Mar 20214:51 pmRNS2019 Redemption Portfolio
5th Mar 20214:50 pmRNSNet Asset Value - Month End Final
26th Feb 20214:20 pmRNSTotal Voting Rights
26th Feb 20217:00 amRNSDirector/PDMR Shareholding
19th Feb 20214:38 pmRNSReturn of Capital to Shareholders
19th Feb 20211:10 pmRNSNet Asset Value - Weekly Estimate
18th Feb 20215:12 pmRNSHolding(s) in Company
16th Feb 20211:48 pmRNSNet Asset Value - Weekly Estimate

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.